Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
10/2005
10/11/2005US6953657 Caspase recruitment domain (CARD); for diagnosis, screening, and treatment of apoptosis via genetic expression
10/11/2005US6953586 Bioabsorbable and biocompatible grafts for administered under the skin of animals comprising solid pellets having animal growth regulators such as trenbolone acetate and melengesterol acetate
10/11/2005US6953577 Human methionine aminopeptidase type 3
10/11/2005US6953576 Controller lymphocytes
10/11/2005US6953575 Methods of treating central nervous system disorders using viral vectors
10/11/2005US6953573 Compounds for eliciting or enhancing immune reactivity to HER-2/neu protein for prevention or treatment of malignancies in which the HER-2/neu oncogene is associated
10/11/2005US6953571 Cosmetic or pharmaceutical composition for topical use to prevent or differ androgenetic alopecia
10/11/2005US6953568 Administering biological conjugates that bind preferentially to endothelial protein C receptor(EPCR), to endothelial cells of vascular systems; genetic translocation; drug delivery
10/11/2005US6953550 Affinity binding-based system for detecting particulates in a fluid
10/11/2005US6953211 Anti-panic opening system for doors
10/11/2005CA2341276C Human anti-factor ix/ixa antibodies
10/11/2005CA2087272C Cd53 cell surface antigen and use thereof
10/08/2005CA2503754A1 Composition and method to prevent or reduce diarrhea and steatorrhea in hiv patients
10/06/2005WO2005093427A1 Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 50 (gpr50)
10/06/2005WO2005093098A1 Differential drug sensitivity
10/06/2005WO2005093082A1 Method of screening compound capable of accelerating or inhibiting apoptosis, apoptosis accelerator and apoptosis inhibitor
10/06/2005WO2005093069A2 Production of mersacidin and its variants in sigh and/or mrsa negative bacillus host cells
10/06/2005WO2005093068A1 Novel protein and promoter
10/06/2005WO2005093064A1 Novel galectin 9 modification protein and use thereof
10/06/2005WO2005093057A1 Truncated dance, dance complex and method of using these
10/06/2005WO2005092928A1 Conjugates of hydroxyalkyl starch and a protein, prepared by reductive amination
10/06/2005WO2005092921A2 Placental growth factor splice variants and their uses
10/06/2005WO2005092918A2 Targeting polypeptide
10/06/2005WO2005092916A1 Novel fermentation products
10/06/2005WO2005092383A1 Preventive/remedy for respiratory diseases
10/06/2005WO2005092379A2 Materials and methods for treatment of cancer
10/06/2005WO2005092370A1 Oral pharmaceutical compositions of lipase-containing products, in particular of pancreatin, containing surfactants
10/06/2005WO2005092369A2 Conjugates of hydroxyethyl starch and erythropoietin
10/06/2005WO2005092368A1 Uses of galectin-2
10/06/2005WO2005092367A1 Composition for promoting adiponectin secretion
10/06/2005WO2005092366A1 TREATMENT OF NEUROLOGICAL CONDITIONS USING COMPLEMENT C5a RECEPTOR MODULATORS
10/06/2005WO2005092365A2 Pharmaceutical use of novispirins
10/06/2005WO2005092364A1 Topical glutathione treatments
10/06/2005WO2005092363A1 Preventive/remedy for diabetic complications using oligopeptide
10/06/2005WO2005092362A2 Pharmaceutical combined preparation containing a therapeutic protein
10/06/2005WO2005092301A1 Insulin highly respirable microparticles
10/06/2005WO2005092288A1 Carbohydrate-derivatized liposomes for targeting cellular carbohydrate recognition domains of ctl/ctld lectins, and intracellular delivery of therapeutically active compounds
10/06/2005WO2005092123A1 Solubilized coq-10 and carnitine
10/06/2005WO2005092069A2 Chimeric infectious dna clones, chimeric porcine circoviruses and uses thereof
10/06/2005WO2005091991A2 Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of skin diseases or disorders
10/06/2005WO2005091956A2 In vitro test system for predicting patient tolerability of therapeutic agents
10/06/2005WO2005091909A2 Methods to increase reverse cholesterol transport in the retinal pigment epithelium (rpe) and bruch’s membrane (bm)
10/06/2005WO2005091856A2 Asthma-related anti-il-13 immunoglobulin derived proteins, compositions, methods and uses
10/06/2005WO2005091801A2 Methods of protein fractionation using high performance tangential flow filtration
10/06/2005WO2005091777A2 Methods and materials relating to insulin growth factor-like (igfl) polypeptides and polynucleotides
10/06/2005WO2005080558A8 Method of modulating cellular processes
10/06/2005WO2005079269A3 Method of treating carcinomas
10/06/2005WO2005077398A3 Arp for inducing granulocytopoiesis
10/06/2005WO2005075646A8 Peptide originating in stress-induced antiapoptosis molecule (iex-1)
10/06/2005WO2005075635A3 Coagulation factor vii/viia variants lacking a functional lipid membrane binding domain
10/06/2005WO2005072893A8 Functionalized colloidal metal compositions and methods
10/06/2005WO2005072261A3 Lactoferrin-treated filament materials
10/06/2005WO2005060350A3 Diastereomeric peptides useful as inhibitors of membrane protein assembly
10/06/2005WO2005046720A3 Diagnosis, prognosis and treatment of pulmonary diseases using foxa2
10/06/2005WO2005042566A3 Antiangiogenicpeptides for treating or preventing endometriosis
10/06/2005WO2005039485B1 Gsk-3 inhibitors and uses thereof
10/06/2005WO2005034876A3 Use of cell lines to produce active therapeutic proteins
10/06/2005WO2005026388A3 The use of eukaryotic genes affecting chromatin separation for diagnosis and treatment of proliferative diseases
10/06/2005WO2005019434A3 Serine protease inhibitors for treatment of bacterial infections
10/06/2005WO2005016254A3 Methods and reagents for treating inflammation and fibrosis
10/06/2005WO2005014641A3 Ciliary neurotrophic factor variants
10/06/2005WO2005000884A8 Poly-gamma-glutamic conjugates for eliciting immune responses directed against bacilli
10/06/2005WO2004113386A3 Modified hirudin proteins and t-cell epitopes in hirudin
10/06/2005WO2004093787A3 Use of glycodendrimer reagents for inhibiting adhesion by microorganisms
10/06/2005WO2004084812A3 Tamandarin analogs and fragments thereof and methods of making and using
10/06/2005WO2004084800A3 A3 receptor-mediated cardioprotective proteins and therapeutic and diagnostic methods of use
10/06/2005WO2004041193A3 HUMAN TYPE II DIABETES GENE-Kv CHANNEL-INTERACTING PROTEIN (KChIP1) LOCATED ON CHROMOSOME 5
10/06/2005US20050223430 Gntiii expression in plants
10/06/2005US20050223419 Mice which are +/- or -/- for the elastin gene as models for vascular disease
10/06/2005US20050223416 C1 inhibitor produced in the milk of transgenic mammals
10/06/2005US20050222402 Dna encoding rat bombesin receptor subtype-3 (brs-3) and uses thereof
10/06/2005US20050222395 New peptide derivatives
10/06/2005US20050222394 Have a hydrophobic linker region and a heparin-binding region, useful as soluble biologics or as surface coatings for medical devices
10/06/2005US20050222392 Anti-idiotype anti-cea antibody molecules and its use as cancer vaccine
10/06/2005US20050222391 Method of constructing antibody
10/06/2005US20050222387 Smac-peptides as therapeutics against cancer and autoimmune diseases
10/06/2005US20050222386 Biomolecule transduction motif sim-2-btm and the use thereof
10/06/2005US20050222384 Useful as prophylactic and therapeutic agent of dysfunction of masticatory, dysphagia, dysgeusia, ozostomia, intra-oral cavity dysphoria, intra-oral cavity infections, intra-oral cavity inflammations, dry eye, ectocornea detachment, keratitis, corneal ulcer, conjunctivitis, stomach and duodenal ulcers
10/06/2005US20050222231 2-Amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivatives; nervous system, psychological, and psychiatric disorders
10/06/2005US20050222221 Cell differentiation, regeneration of pancreas epithelial cells to insulin producing beta cells; administering a dipeptidyl-peptidase activators
10/06/2005US20050222214 Administering conjugate having a polyethylene glycol (PEG) moiety covalently bound to the serine residue of antide for therapy of hormonal dependent cancer, endometriosis, uterine fibroids, uterine myoma, and leutinizing hormone (LH) surge in woman undergoing in vitro fertilization
10/06/2005US20050222120 Peptides derivatives comprising thiazepine group for the treatment of hyperlipidermic conditions
10/06/2005US20050222119 Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4
10/06/2005US20050222093 Methods for restoring cognitive function following systemic stress
10/06/2005US20050222092 Use of s1p receptor agonists in heart diseases
10/06/2005US20050222073 Antisense modulation of thyroid hormone receptor interactor 6 expression
10/06/2005US20050222062 Decoy for treating and/or preventing th2 cytokine-associated allergic disease, gata3 mutant protein and medicinal compositions containing the same
10/06/2005US20050222061 Means and methods for the specific inhibition of genes in cells and tissue of the cns and/or eye
10/06/2005US20050222058 Antisense modulation of mucin 1, transmembrane expression
10/06/2005US20050222057 Intact minicells as vectors for dna transfer and gene therapy in vitro and in vivo
10/06/2005US20050222047 Compounds as enzyme inhibitors to treat hepatitis with viricides
10/06/2005US20050222046 Pharmaceutical preparations of glutathione and methods of administration thereof
10/06/2005US20050222045 Novel derivatives of 2-hydroxytetrahydrofuran and their use as medicaments
10/06/2005US20050222044 At4 receptor ligands as angiogenic, anti-angiogenic, and anti-tumor agents
10/06/2005US20050222043 Use of proteasome inhibitor in the treatment of fibrotic diseases
10/06/2005US20050222042 Modifying N-methyl-D-aspartate function without completely blocking the receptor or adversely affecting other neuronal proteins with the use of generalized kinase inhibitors with an oligopeptide that inhibits interaction of the unique domain of the tyrosine kinase Src enzyme and the receptor complex
10/06/2005US20050222041 oligopeptides capable of stimulating neural cell adhesion molecule (NCAM) signalling and/or interfering with cell adhesion, used for treatment of nervous system disorders
10/06/2005US20050222040 Vertebrate peptide modulators of lipid metabolism
10/06/2005US20050222039 Animal treatment
10/06/2005US20050222038 Protection against ischemia and reperfusion injury
1 ... 1366 1367 1368 1369 1370 1371 1372 1373 1374 1375 1376 1377 1378 1379 1380 1381 1382 1383 1384 1385 1386 ... 3163